O
ONCOLYTICS BIOTECH INC
ONCYCIK 0001129928NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaCAFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-28.76M
Total Assets
$7.58M
Equity
$-3.80M
Shares Out
116.13M
Op. Cash Flow
$-20.11M
Business
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered oncolytic immunotherapeutic that modulates the tumor microenvironment to enhance anti-tumor innate and adaptive immune responses. The company’s primary product candidate is pelareorep, a proprietary reovirus isolate evaluated as monotherapy and in combination with chemotherapy, checkpoint inhibitors and other immuno-oncology approaches. Business activities are organized around clinical development programs, including breast cancer and gastrointestinal cancer (GOBLET platform), patent protection, and strategic partnerships. Clinical trials and regulatory interactions occur across the United States, Canada, Europe and other international study sites.
Summary from filing dated 2025-03-07
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Research and development | 13 | 15 | |
| General and administrative | 15 | 10 | |
| Total operating expenses | 29 | 26 | |
| Loss from operations | −29 | −26 | |
| Change in fair value of warrant derivative | 153,000 | 1 | |
| Fair value loss from Standby Equity Purchase Agreement (SEPA Arrangement) | −388,000 | 0 | |
| Foreign exchange (loss) gain | −106,000 | 699,000 | |
| Interest income | 386,000 | 975,000 | |
| Total other income, net | 45,000 | 3 | |
| Loss before income taxes | −29 | −23 | |
| Income tax expense | −79,000 | −95,000 | |
| Net loss | −29 | −23 | |
| Translation adjustments | −136,000 | −526,000 | |
| Comprehensive loss | −29 | −23 | |
| Basic net loss per common share (in dollars per share) | −0.3 | −0.3 | |
| Diluted net loss per common share (in dollars per share) | −0.3 | −0.3 | |
| Weighted average number of common shares used in computing net loss per share, basic (in shares) | 96 | 76 | |
| Weighted average number of common shares used in computing net loss per share, diluted (in shares) | 96 | 76 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 5 | 11 | — | |
| Other receivables | 573,000 | 47,000 | — | |
| Prepaid expenses | 1 | 1 | — | |
| Total current assets | 7 | 12 | — | |
| Property and equipment, net | 228,000 | 286,000 | — | |
| Right-of-use assets | 510,000 | 699,000 | — | |
| Total assets | 8 | 13 | — | |
| Accounts payable | 4 | 756,000 | — | |
| Accrued liabilities | 2 | 3 | — | |
| Other liabilities | 0 | 1 | — | |
| Operating lease liabilities, current | 193,000 | 200,000 | — | |
| Warrant derivative | 77,000 | 230,000 | — | |
| Total current liabilities | 6 | 5 | — | |
| Contract liability | 5 | 5 | 5 | |
| Operating lease liabilities, non-current | 370,000 | 561,000 | — | |
| Total liabilities | 11 | 10 | — | |
| Commitments and contingencies (Note 11) | — | — | — | |
| Common shares, no par value; Unlimited shares authorized as of December 31, 2025 and 2024; 108,021,271 and 80,020,131 shares issued and outstanding as of December 31, 2025 and 2024, respectively. | 0 | 0 | — | |
| Additional paid-in capital | 419 | 398 | — | |
| Accumulated other comprehensive income | 6 | 6 | — | |
| Accumulated deficit | −429 | −401 | — | |
| Total shareholders (deficit) equity | −4 | 3 | 20 | |
| Total liabilities and shareholders' (deficit) equity | 8 | 13 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Depreciation of property and equipment | 70,000 | 87,000 | |
| Noncash lease expense | 288,000 | 297,000 | |
| Stock-based compensation expense | 3 | 2 | |
| Issuance of shares for services | 3 | 0 | |
| Unrealized foreign exchange gains | −137,000 | −809,000 | |
| Value of shares issued for SEPA Arrangement commitment fees | 440,000 | 0 | |
| Other receivables | 3,000 | −39,000 | |
| Prepaid expenses | 580,000 | 991,000 | |
| Accounts payable | 3 | 4,000 | |
| Accrued liabilities | −360,000 | 884,000 | |
| Pancreatic Cancer Action Network (PanCAN) receivables and payables | −2 | 936,000 | |
| Operating lease liabilities | −293,000 | −253,000 | |
| Net cash used in operating activities | −20 | −20 | |
| Acquisition of property and equipment | −6,000 | −174,000 | |
| Net cash used in investing activities | −6,000 | −174,000 | |
| Proceeds from exercise of warrant derivative | 0 | 47,000 | |
| Proceeds from stock option exercise | 32,000 | 0 | |
| Other | −27,000 | 0 | |
| Net cash provided by financing activities | 14 | 5 | |
| Effect of exchange rate changes on cash and cash equivalents | 121,000 | −289,000 | |
| Net decrease in cash and cash equivalents | −6 | −15 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro